Karma Biotechnologies

Therapeutics & Med Devices
Andrew Gray
Alan Johnson

Karma Biotechnologies is developing the first “Xavine” - a vaccine-like treatment to prevent the unhealthy immune system activity exhibited in autoimmune disorders. The founders are well-established scientists in immunology and chemical biology, bringing a good mix of in-depth scientific knowledge and creative biochemical engineering talent to the enterprise.

The past 30 years of the "War on Cancer" have produced a wealth of knowledge regarding how cancers are able to evade the body's immune system.
Treatments to prevent unhealthy immune system activity